Renvela Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent
AbstractEnarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non-calcium-based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open-label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was...
Source: Clinical Pharmacology in Drug Development - November 18, 2023 Category: Drugs & Pharmacology Authors: Sudhakar M. Pai, Hiroyuki Yamada Tags: Original Article Source Type: research

Efficacy and safety of ferric citrate on hyperphosphatemia among Chinese patients with chronic kidney disease undergoing hemodialysis: a phase III multicenter randomized open-label active-drug controlled study
CONCLUSION: Ferric citrate capsules have good efficacy and safety in the control of hyperphosphatemia in adult patients with CKD undergoing hemodialysis. Efficacy is not inferior to sevelamer carbonate. The TEAEs were mostly mild and tolerated by the patients.PMID:37812931 | DOI:10.1159/000534484 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - October 9, 2023 Category: Urology & Nephrology Authors: Yong Wang Xiangmei Chen Hanyu Zhu Zhiyong Guo Yibin Yang Ping Luo Yani He Yan Xu Daxi Ji Xinlu Gao Xiuli Sun Changying Xing Yu Wang Xiaohui Wang Shuping Zhao Yan Guan Hongli Lin Aimin Zhong Hua Shui Fengmin Shao Lu Lv Yuehong Yan Xiaokun Sun Lei Zhang Source Type: research

High Phosphate Binding Capacity of Lanthanum Dioxycarbonate With a Low Medication Volume: Comparison With Commercially Available Phosphate Binders
CONCLUSIONS: Lanthanum dioxycarbonate has the lowest daily phosphate binder dose volume and the smallest volume required to bind 1 g of phosphate compared to all other commercially available phosphate binders. A randomized trial that compares gastrointestinal tolerability across binders would be warranted to demonstrate acceptability and adherence in the target population. .PMID:37231835 | DOI:10.1159/000530989 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - May 26, 2023 Category: Urology & Nephrology Authors: Stuart M Sprague Guru Reddy Douglas Jermasek Pramod Gupta Source Type: research

Phosphate intake and removal in predominantly vegetarian patients on twice-weekly hemodialysis
Conclusion: Twice-weekly dialysis is often practised in resource-limited Asian countries. However, due to a predominantly vegetarian diet, hyperphosphatemia was noted only in up to half of the patients, despite twice-weekly hemodialysis schedules. This reinforces the fact that plant-based dietary phosphate is less well absorbed. (Source: Indian Journal of Nephrology)
Source: Indian Journal of Nephrology - December 20, 2022 Category: Urology & Nephrology Authors: Namrata Sarvepalli Rao Abhilash Chandra Manish Kulshreshta Poonam Tiwari Sai Saran Ayush Lohiya Source Type: research

Calciphylaxis in an adolescent without renal failure
The patient was a 15-year-old male adolescent with painful and pruritic erythematous indurated nodules on his legs and hands that progressed to ulcerated lesions over 1 month (figure 1). The patient had medical history of juvenile idiopathic arthritis, hypothyroidism and hyperphosphatemia. He was treated with prednisolone, methotrexate, levothyroxine and sevelamer carbonate. Laboratory tests (complete blood count, biochemical tests, blood complement level, liver function tests, renal function tests) were within the normal limits except an elevated C reactive protein (53 mg/L, normal range <6 mg/L), erythrocyte sedimenta...
Source: Archives of Disease in Childhood - November 17, 2022 Category: Pediatrics Authors: Safavi, M., Sadeghi, P., Hosseinlou, S. Tags: Miscellanea Source Type: research

Calcinosis of the internal jugular vein: Interesting presentation of tertiary hyperparathyroidism
Tumoral calcinosis with calcification of soft tissues is reported in dialysis patients. Changing from peritoneal dialysis to hemodialysis, discontinuing Vitamin D analogue therapy, changing sevelamer carbonate to lanthan(III)-carbonate, following a low-calcium/low-phosphate diet, and surgery can be treatment options. Parathyroidectomy or excision of calcified tissue are surgical options. AbstractTumoral calcinosis is a severe complication of hemodialysis. A 49-year-old male on dialysis for end-stage renal disease developed a large calcified retropharyngeal mass. This caused stridor and dyspnea, necessitating an emergency a...
Source: Clinical Case Reports - August 8, 2022 Category: General Medicine Authors: Courtney B. Shires, Mona Shete Tags: CASE REPORT Source Type: research

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults
AbstractVadadustat is a hypoxia-inducible factor prolyl-hydroxylase inhibitor being developed for the treatment of anemia in patients with chronic kidney disease. Sequelae of chronic kidney disease include hyperphosphatemia and anemia, which are frequently treated with phosphate binders and iron supplements, respectively. Two studies evaluating the pharmacokinetics, safety, and tolerability of a single oral dose of vadadustat coadministered with a phosphate binder or iron supplement were conducted in healthy adult participants. In study 1, 54 healthy women and men were administered vadadustat (300 mg) alone and 1 hour befo...
Source: Clinical Pharmacology in Drug Development - February 16, 2022 Category: Drugs & Pharmacology Authors: Susan K. Paulson, Jimena Martinez, Rishikesh Sawant, Steven K. Burke, Ajit Chavan Tags: Original Article Source Type: research